渤健|速递|开发创新眼科基因疗法,ViGeneron与渤健达成全球性合作协议( 二 )
About ViGeneron
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, a less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany. For further information, please visit www.vigeneron.com.
注:本文旨在介绍医药健康研究,不是治疗方案推荐 。如需获得治疗方案指导,请前往正规医院就诊 。
推荐阅读
- 人类免疫缺陷病毒|深港团队开发艾滋病新抗体:动物实验中能100%预防HIV
- 阿尔茨海默病|速递|脑萎缩减少65%!“不用吃药”的阿尔茨海默病疗法结果积极
- 结直肠癌|多动少坐——为结直肠癌幸存者带来获益|研究速递
- 实体瘤|速递|治疗实体瘤,第二代STING激动剂首个人体试验中期数据积极
- 疫苗|《科学》子刊:中国团队开发纳米癌症疫苗,有望抑制肿瘤复发
- 溃疡性结肠炎|溃疡性结肠炎患者:低脂肪高纤维饮食,你值得拥有!|研究速递
- 葛兰素史克|未来10年造福超过25亿人,葛兰素史克将重点开发哪些项目?(附PPT)
- 克罗恩病|饮食治疗:缓解克罗恩病症状,试试地中海饮食|研究速递
- 肿瘤|OCC 2021|新学科,新进展——肿瘤心脏病学论坛前沿速递
- noses|会议速递|中国胃肠NOSES百场公益系列学术活动巡讲—苏北站